Fluorinated Ionizable Lipids for Efficient Spleen-Targeted mRNA Delivery in Cancer Immunotherapy
Journal of the American Chemical Society · 12.11.2025 · 147 (45) · 41756-41767
DOI: 10.1021/jacs.5c13982 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, online erschienen am 29.10.2025. Verfasst von Yanhao Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of the University of Science and Technology of China, and State Key Laboratory of Precision and…. Hauptthemen laut MEDLINE: RNA, Messenger, Spleen, Lipids, Immunotherapy. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: University of Science and Technology of China, China Postdoctoral Science Foundation, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Efficient and selective mRNA delivery to immune-related organs, particularly the spleen, remains a major barrier to the broader clinical translation of mRNA therapeutics. Here, leveraging the clinically approved SM-102/ALC-0315 ionizable lipid scaffold, we rationally designed a combinatorial library of fluorinated ionizable lipids (FILs) by systematically modulating hydrophobic tails and fluorine stoichiometry. Through synthesis and evaluation of 74 candidate FILs, we identify SSC6F5 lipid nanoparticles (LNPs) as a lead formulation with exceptional spleen-targeting specificity (>90%) across intravenous, intramuscular, and subcutaneous administrations. Compared to clinically approved SM102 LNPs and spleen-tropic SM102/18PA (SORT) LNPs, intravenously administered SSC6F5 LNPs achieve 10.6-fold and 63.1-fold higher splenic mRNA transfection, respectively. Proteomic analysis of protein corona on SSC6F5 LNPs reveals significant enrichment of apolipoprotein D (Apod) and reduction in apolipoprotein H (Apoh), implicating a novel endogenous recognition pathway driving enhanced spleen targeting. Functionally, SSC6F5 LNPs enable efficient genome editing in splenic macrophages, dendritic cells, T cells, and B cells in Ai9 mice, and elicit potent CD8+ T cell and humoral responses in a B16-OVA murine melanoma model, resulting in significant tumor growth inhibition. These findings establish fluorinated lipids as a mechanistically distinct and translationally versatile platform for precision spleen-targeted mRNA delivery in gene editing and cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The First Affiliated Hospital of the University of Science and Technology of China, and State Key Laboratory of Precision and Intelligent Chemistry, University of Science and Technology of China,…
- School of Biomedical Engineering, Suzhou Institute for Advanced Research, University of Science and Technology of China, Suzhou 215123, Jiangsu ,China.
ORCID-Profile: Jinming Hu, Shiyong Liu
Förderung
- University of Science and Technology of China
- China Postdoctoral Science Foundation
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Y., Shao, B., Jiang, K., Cen, J., Liu, Y., Tan, J., Zhang, L., Li, K., You, C., He, Z., Zhang, G., Chen, M., Hu, J., & Liu, S. (2025). Fluorinated Ionizable Lipids for Efficient Spleen-Targeted mRNA Delivery in Cancer Immunotherapy. Journal of the American Chemical Society, 147(45), 41756-41767. https://doi.org/10.1021/jacs.5c13982
Vancouver
Zhang Y, Shao B, Jiang K, Cen J, Liu Y, Tan J, et al. Fluorinated Ionizable Lipids for Efficient Spleen-Targeted mRNA Delivery in Cancer Immunotherapy. Journal of the American Chemical Society. 2025;147(45):41756-41767. doi:10.1021/jacs.5c13982
BibTeX
@article{Zhang2025,
author = {Zhang, Yanhao and Shao, Bing and Jiang, Kai and Cen, Jie and Liu, Yang and Tan, Jiajia and Zhang, Lin and Li, Keyu and You, Chengying and He, Zhihua and Zhang, Guoying and Chen, Minglong and Hu, Jinming and Liu, Shiyong},
title = {Fluorinated Ionizable Lipids for Efficient Spleen-Targeted mRNA Delivery in Cancer Immunotherapy},
journal = {Journal of the American Chemical Society},
year = {2025},
volume = {147},
number = {45},
pages = {41756--41767},
doi = {10.1021/jacs.5c13982}
}
EUVIMED